Dalfaz

Dalfaz is a medicine used for the treatment and prevention of prostate diseases. It is produced by the pharmaceutical company Sintelabo Group in France and is available in two dosage forms: 2.5 mg film-coated tablets and 5 mg retard film-coated tablets. The active substance is alfuzosin.

Dalfaz is used for the symptomatic treatment of dysuria, which can be caused by both irritative and obstructive manifestations of benign prostatic hyperplasia. It may be used in patients who need to avoid surgery or in older patients whose disease is rapidly progressing.

Despite the effectiveness of Dalfaz, it has contraindications and side effects. It should not be prescribed to patients with hypersensitivity to alfuzosin, or to patients with a history of orthostatic hypotension or while taking other alpha-blockers. Side effects may include headache, dizziness, weakness, drowsiness, asthenia, orthostatic hypotension, tachycardia, dry mouth, nausea, epigastric pain, diarrhea, swelling, redness of the skin, skin rashes and itching.

Dalfaz may interact with other medicines such as calcium channel blockers and general anesthetics. When taken simultaneously, the risk of developing arterial (including orthostatic) hypertension and collapse increases. When prescribing Dalfaz to patients with coronary heart disease, caution should be exercised, and if a worsening of angina is observed during therapy, the drug should be discontinued.

In general, Dalfaz is an effective drug for the treatment and prevention of prostate diseases. However, before using it, you should consult your doctor and read the instructions for use to avoid side effects and contraindications.